Market size: what is knowable

Estimates disagree

Published estimates for overlapping scopes differ by multiples:

• Meticulous Research: $1.8B to $2.4B in 2026 for a broad NAMs scope, rising to $12B to $16B by 2036.
• Future Market Insights: $0.74B in 2026 for NAM nonclinical testing, $1.9B by 2036.
• DataM Intelligence: organ-on-chip alone at $2.66B by 2033, a 36% CAGR.

Scope definitions, base years and methods differ and are rarely disclosed. Treat these as directional at best. The Market Size chart on this site shows the spread.

More reliable anchors

• Public company revenue: Certara $418.8M (FY2024); Simulations Plus $79.1M (FY2025).
• Disclosed transactions: MatTek at $80M on more than $20M of 2024 sales; IQVIA agreed to pay about $145M for five Charles River discovery sites.
• Venture census: Tracxn counts 46 organ-on-chip companies with about $478M raised, and 124 organoid research model startups.
• Incumbent exposure: Charles River's estimate of about $50M a year at risk.

How to read this site's numbers

Deal totals here are lower bounds built from public sources. Undisclosed deals count toward deal counts but not dollar totals.